These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements
The change in pace is completely normal and doesnt mean your plan has stopped working
Retatrutide is an investigational weekly injection targeting three hormone receptors (GLP1, GIP and glucagon) to support weight loss
Retatrutide is not currently licensed by the MHRA for weight loss in the UK, so it cannot legally be prescribed or supplied as an approved weight loss treatment
In a landmark Phase 2 trial published in the New England Journal of Medicine, participants receiving the 12 mg dose experienced mean weight loss of 24.2% at 48 weeks, significantly exceeding results from earlier GLP-1 or dual-agonist therapies
Overall the research confirmed an old observation that oral and intravenous glucose prompted different physiological responses (Marks, Samols)